Loading...
XNAS
VIVS
Market cap4mUSD
Dec 05, Last price  
2.32USD
1D
1.31%
1Q
-7.57%
Jan 2017
-99.71%
IPO
-99.80%
Name

Organovo Holdings Inc

Chart & Performance

D1W1MN
XNAS:VIVS chart
P/E
—
P/S
29.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-25.73%
Rev. gr., 5y
-42.01%
Revenues
144k
+32.11%
01,197,000379,000571,0001,483,0004,230,0004,603,0003,091,0002,196,00001,500,000370,000109,000144,000
Net income
-2m
L-83.04%
-147,817-43,553,000-25,848,000-30,082,000-38,575,000-38,447,000-34,803,000-26,635,000-18,710,000-16,826,000-11,448,000-17,259,000-14,671,000-2,488,000
CFO
-9m
L-35.43%
-109,425-9,693,000-15,561,000-19,601,000-29,368,000-29,185,000-28,857,000-20,375,000-14,882,000-13,323,000-8,453,000-12,408,000-14,653,000-9,461,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
URL
https://organovo.com/
IPO date
Aug 02, 2013
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT